Manhattan, New York Clinical Trials

A listing of Manhattan, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 423 clinical trials
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

medulloblastoma recurrent
cancer
genetic alteration
percutaneous endoscopic gastrostomy
ascites
Laura and Isaac Perlmutter Cancer Center at NYU Langone
 (2.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

neurofibroma
neutrophil count
crizotinib
measurable disease
schwartz
Memorial Sloan Kettering Cancer Center (Site 210)
 (1.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
Targeted Fortification of Donor Breast Milk in Preterm Infants

This study is a randomized controlled trial comparing standard fortification of donor breast milk to targeted fortification of donor breast milk in preterm infants. The purpose of the study is to determine if there is a benefit to target fortifying donor breast milk in the preterm population. The investigators hypothesize …

Columbia University Medical Center/ New York - Presbyterian
 (4.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

kras g12c mutation
metastatic malignant solid tumor
solid tumour
solid tumor
kras
Memorial Sloan Kettering Cancer Center
 (1.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

prostate cancer
cancer
abiraterone
antiandrogen therapy
hormone therapy
Memorial Sloan-Kettering Cancer Center
 (1.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +5 other locations
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.

bilateral oophorectomy
measurable disease
oophorectomy
systemic therapy
hysterectomy
John Theurer Cancer Center at Hackensack University Medical Center
 (8.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
ctgov trial 2

    dddd

Test Site
 (2.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

lenalidomide
refractory multiple myeloma
ixazomib
immunotherapeutic agent
thalidomide
Investigational Site Number 8400001
 (1.5 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +7 other locations
Test Campaign Performance Report  

Test Campaign Performance Report

Site Test A
 (4.8 away)
  • 0 views
  • 19 Feb, 2024
  • +2 other locations
Test CPR 2  

Test CPR 2

Site Test A
 (4.8 away)
  • 0 views
  • 19 Feb, 2024
  • +2 other locations